Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations
Medpace reported Q3 2026 revenue of $716M, beating estimates by $2.3M, with EPS of $4.84, a 9.3% beat. Adjusted EBITDA was $172.1M, an 8% beat. The company reconfirmed its full-year revenue guidance of $2.85B and raised EPS guidance to $18.15, a 3.2% beat. Operating margin improved to 23.1%, while free cash flow margin declined to 27.4%.
How this was made
The 30-second read
Why it matters
The combination of in-line revenue, GAAP EPS beat, adjusted EBITDA beat, and reconfirmed full-year guidance suggests a generally constructive earnings outcome, with the main caution flag being weaker free cash flow margin versus the prior-year quarter.
Market read
Traders can reassess near-term expectations for Medpace’s earnings power and guidance credibility based on the reported beats and unchanged full-year targets.
What to watch
The article notes FCF margin decline (27.4% vs 35.7% prior-year quarter), which may signal working-capital or timing effects not captured by EPS/EBITDA.
Background
The piece summarizes Medpace’s Q3 2026 performance versus analyst estimates and reiterates full-year guidance midpoints.
Ticker impact
Medpace reported Q3 2026 revenue of $716M and GAAP EPS $4.84, and reconfirmed full-year revenue guidance at $2.85B midpoint.
Likely upward pressure as the market digests in-line revenue but beats in GAAP EPS and EBITDA, plus unchanged full-year guidance.
The article provides multiple beat metrics (GAAP EPS, adjusted EBITDA, and full-year GAAP EPS and EBITDA guidance) while revenue is only in line; reconfirmed guidance reduces downside risk.
Market effects
Positive read-through for clinical research outsourcing demand expectations, though the article is single-company focused.
Limited broader regional impact; primarily affects US small/mid-cap healthcare services sentiment.
Low global spillover beyond investor sentiment for CRO peers.
Counterpoint
Free cash flow margin fell sharply year over year, which could temper enthusiasm if investors prioritize cash conversion over earnings.
Key entities
- companyMedpace
NASDAQ-listed CRO reporting Q3 2026 results and reconfirmed full-year guidance.
